Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

<p style="text-align:justify;"> To improve strategies for the treatment of BRAF-mutant advanced colorectal cancer (aCRC) patients, we examined individual data from patients treated with chemotherapy alone in three randomised trials to identify points on the treatment pathway where o...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Seligmann, JF, Fisher, D, Smith, CG, Richman, SD, Elliott, F, Brown, S, Adams, R, Maughan, T, Quirke, P, Cheadle, J, Seymour, M, Middleton, G
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Oxford University Press 2016

Παρόμοια τεκμήρια

2530
ανά: Bernadette McKinney
Έκδοση: (2017-09-01)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
ανά: Adams, R, κ.ά.
Έκδοση: (2017)

BRAF and NRAS locus-specific variants have different outcomes on survival to colorectal cancer
ανά: Summers, MG, κ.ά.
Έκδοση: (2016)

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS and NRAS
ανά: Adams, R, κ.ά.
Έκδοση: (2016)

Targeting mutant BRAF in colorectal cancer
ανά: Carroll David, κ.ά.
Έκδοση: (2013-01-01)

Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification
ανά: Seymour, M, κ.ά.
Έκδοση: (2011)

The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer
ανά: Forsythe, N, κ.ά.
Έκδοση: (2018)

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
ανά: Susan D. Richman, κ.ά.
Έκδοση: (2011-01-01)

BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
ανά: Vinay K. Pattalachinti, κ.ά.
Έκδοση: (2025-02-01)

Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT
ανά: Louise C Brown, κ.ά.
Έκδοση: (2022-12-01)

Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models
ανά: Federica Maione, κ.ά.
Έκδοση: (2024-06-01)

Chromosomal instability in BRAF mutant, microsatellite stable colorectal cancers.
ανά: Catherine E Bond, κ.ά.
Έκδοση: (2012-01-01)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
ανά: Elisa Grassi, κ.ά.
Έκδοση: (2021-06-01)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
ανά: Maughan, T, κ.ά.
Έκδοση: (2009)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
ανά: Yasar Subutay Peker, κ.ά.
Έκδοση: (2018-01-01)

DEFICIENT MISMATCH REPAIR (DMMR) AND BRAF MUTATION (MT) STATUS IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC): A META-ANALYSIS OF THE CAIRO, CAIRO2, COIN AND FOCUS STUDIES
ανά: Venderbosch, S, κ.ά.
Έκδοση: (2012)

Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer - Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification
ανά: Middleton, G, κ.ά.
Έκδοση: (2011)

Pipeline electrical and instrumentation : switches and transmitters (CT25.30. and 31)
ανά: 599270 National Center for Construction Education and Research
Έκδοση: (2002)

Design of Collection Module of Underground Personnel Information Based on CC2530
ανά: ZHENG Mao-quan, κ.ά.
Έκδοση: (2012-06-01)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
ανά: Seymour, M, κ.ά.
Έκδοση: (2013)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial
ανά: Seymour, M, κ.ά.
Έκδοση: (2013)

Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia
ανά: M. Yu. Fedyanin, κ.ά.
Έκδοση: (2021-06-01)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
ανά: Ting Xu, κ.ά.
Έκδοση: (2022-06-01)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
ανά: Ting Xu, κ.ά.
Έκδοση: (2023-05-01)

Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.
ανά: Smith, C, κ.ά.
Έκδοση: (2013)

Design of Mine-used Wireless Roof Pressure Sensor Based on CC2530
ανά: WU Yao-ming, κ.ά.
Έκδοση: (2012-12-01)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
ανά: Maughan, T, κ.ά.
Έκδοση: (2010)

RNF43 is associated with genomic features and clinical outcome in BRAF mutant colorectal cancer
ανά: Peipei Shang, κ.ά.
Έκδοση: (2023-06-01)

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
ανά: Evelina Miele, κ.ά.
Έκδοση: (2020-02-01)

Braf-Mutant Melanomas: Biology and Therapy
ανά: Elvira Pelosi, κ.ά.
Έκδοση: (2024-12-01)

Dabrafenib for treatment of BRAF-mutant melanoma
ανά: Kainthla R, κ.ά.
Έκδοση: (2013-12-01)

2530 Relationship between preexisting pain and completion of a community-based wellness program
ανά: Chantay Young, κ.ά.
Έκδοση: (2018-06-01)

SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer.
ανά: Ida V Lundberg, κ.ά.
Έκδοση: (2014-01-01)

Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
ανά: Pan JH, κ.ά.
Έκδοση: (2018-08-01)

Identification of anticancer drugs to radiosensitise <i>BRAF</i>-wild-type and mutant colorectal cancer
ανά: Rebecca Carter, κ.ά.
Έκδοση: (2019-06-01)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
ανά: Maughan, T, κ.ά.
Έκδοση: (2010)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
ανά: Wood, G, κ.ά.
Έκδοση: (2017)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
ανά: Eva Marie Erfurth, κ.ά.
Έκδοση: (2024-12-01)

Mutant-selective degradation by BRAF-targeting PROTACs
ανά: Shanique Alabi, κ.ά.
Έκδοση: (2021-02-01)

Preoperative prediction of early recurrence in patients with BRAF mutant colorectal cancer using a intergrated nomogram
ανά: Zhenbin Jin, κ.ά.
Έκδοση: (2024-10-01)